Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment

The tumor microenvironment is rich with immune-suppressive macrophages that are associated with cancer progression and resistance to immune checkpoint therapy. Using pre-treatment tumor biopsies complemented with single-cell RNA sequencing (RNA-seq), we characterize intratumoral immune heterogeneity...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports (Cambridge) 2020-07, Vol.32 (1), p.107873-107873, Article 107873
Hauptverfasser:	Qu, Yan, Wen, Ji, Thomas, Graham, Yang, Wenjing, Prior, Weiwei, He, Wenqian, Sundar, Purnima, Wang, Xiao, Potluri, Shobha, Salek-Ardakani, Shahram
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal, Humanized - pharmacology Avelumab Biomarkers, Tumor - metabolism Cell Line, Tumor Chemokine CXCL9 - metabolism Cxcl9 Female Immune Checkpoint Inhibitors - pharmacology Inflammation - pathology Mice, Inbred BALB C Models, Biological Monocytes - drug effects Monocytes - metabolism PD-L1 resistance scRNA-Seq Treatment Outcome tumor associated macrophage Tumor-Associated Macrophages - drug effects Tumor-Associated Macrophages - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!